Core Viewpoint - Guangdong Province's Medical Insurance Bureau has announced the optimization and integration of medical service pricing for dialysis, ultrasound, and traditional Chinese medicine, ensuring that the financial burden on dialysis patients does not increase [1][2]. Group 1: Dialysis Service Pricing - The previous 32 items related to "machine-assisted plasma exchange" have been consolidated into 21 items under "blood dialysis fees," with a provincial maximum price set at 390 yuan per session, covering all necessary procedures and resources [2]. - The maximum price for peritoneal dialysis (manual) is set at 45 yuan per session, while automated peritoneal dialysis is priced at 16 yuan per hour [2]. - Public medical institutions must charge according to the integrated pricing for dialysis services and cannot charge separately for different components of the service [2][3]. Group 2: Traditional Chinese Medicine and Ultrasound Pricing - The previous 60 items for "ordinary acupuncture" have been consolidated into 10 pricing items for acupuncture methods, while 105 items for "fracture manual reduction" have been reduced to 9 items for orthopedic methods [4]. - The pricing for ultrasound services has been streamlined from 84 items to 13, with ultrasound report services now included in the ultrasound pricing, eliminating separate charges for reports [4]. - The maximum prices for the newly integrated services must not exceed the provincial limits, with local prices allowed to be lower [4].

中国市场充满活力——访万益特全球首席执行官陶 克瑞 "中国经济稳步增长和对医疗创新的承诺是塑造全球行业未来的重要驱动力。中国在数字医疗、扩 大优质医疗服务可及性方面所作的努力，与万益特致力于改善患者治疗效果、为专业医护人员提供支持 的目标高度契合。"在中国发展高层论坛2025年年会期间，万益特公司全球首席执行官陶克瑞在接受经 济日报记者采访时表示。 万益特是一家重要的脏器疗法公司，其产品线主要包括腹膜透析、血液透析、急重症治疗三大领 域。自1989年进入中国市场以来，万益特已经建立了涵盖研发、制造、销售及服务的完整产业链。公司 中国总部落户上海，拥有一家世界级研发中心、一家技术服务中心，并在苏州、广州、天津建立了生产 基地。 作为全球第二大医疗器械市场，中国市场充满活力，民众追求高品质医疗健康服务，对个性化和多 元化治疗方案的需求潜力巨大。陶克瑞指出，"中国在数字医疗、居家治疗和慢性病管理方面实行的利 好政策与万益特'延续生命之旅、拓展无限可能'这一使命非常契合，同时，中国在生物医学研究、人工 智能+大健康等领域的人才储备丰富，是全球重要的创新中心。万益特希望继续借助本土人才优势，持 续探索创新解决方案，助力 ...